Previous 10 | Next 10 |
2023-03-30 01:38:53 ET Addex Therapeutics press release ( NASDAQ: ADXN ): FY GAAP EPS of -CHF 0.46. Income is primarily from our funded research collaboration with Indivior. Income decreased by CHF 1.7 million to CHF 1.4 million in 2022 compared to CHF 3.2 million in ...
CHF 7.0M ($ 7. 4 M ) of c ash and cash equivalents at Dec ember 31, 202 2 ADX71149 Phase 2 study in epilepsy cohort 1 compl etes part 1 – independent interim review committee (IRC) recommendation expected ...
Geneva, Switzerland, March 2 8 , 20 2 3 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its full-year 2022 financ...
Geneva, Switzerland, March 16, 202 3 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will participate in the following conferences during the fi...
2023-03-14 10:08:44 ET Gainers: PaxMedica ( PXMD ) +36% . Avid Bioservices ( CDMO ) +25% . Amylyx Pharmaceuticals ( AMLX ) +17% . Euda Health ( EUDA ) +17% . Addex Therapeutics ( ADXN ) +11% . Losers: Rapt Therap...
2023-03-14 08:22:30 ET Western Alliance Bancorporation ( WAL ) +36% takes additional steps to bolster liquidity. PacWest Bancorp ( PACW ) +34% . First Foundation ( FFWM ) +20% . Metropolitan Bank Holding ( MCB ) +14% . Moment...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 9 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announce...
Data to be reviewed by independent interim review committee (IRC) to keep study blinded Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland , J anuary 19 , 202 3 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and develo...
Addex Therapeutics ( NASDAQ: ADXN ) and Indivior ( OTCPK:INVVY ) ( OTCPK:IZQVF ) extended the research term until June 30, 2023 of their collaboration to develop therapies for substance use disorder. The companies had signed an agreement to discover novel oral gamma-a...
News, Short Squeeze, Breakout and More Instantly...
Addex Therapeutics Ltd Company Name:
ADXN Stock Symbol:
NASDAQ Market:
Addex Therapeutics Ltd Website:
2024-07-19 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...